| Spike mutation D614G alters SARS-CoV-2 fitness JA Plante, Y Liu, J Liu, H Xia, BA Johnson, KG Lokugamage, X Zhang, ... Nature 592 (7852), 116-121, 2021 | 1802 | 2021 |
| Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis BA Johnson, X Xie, AL Bailey, B Kalveram, KG Lokugamage, A Muruato, ... Nature 591 (7849), 293-299, 2021 | 849* | 2021 |
| The N501Y spike substitution enhances SARS-CoV-2 infection and transmission Y Liu, J Liu, KS Plante, JA Plante, X Xie, X Zhang, Z Ku, Z An, D Scharton, ... Nature 602 (7896), 294-299, 2022 | 563* | 2022 |
| Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant Y Liu, J Liu, BA Johnson, H Xia, Z Ku, C Schindewolf, SG Widen, Z An, ... Cell reports 39 (7), 2022 | 414 | 2022 |
| Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape Z Ku, X Xie, E Davidson, X Ye, H Su, VD Menachery, Y Li, Z Yuan, ... Nature communications 12 (1), 469, 2021 | 163 | 2021 |
| Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants Z Ku, X Xie, PR Hinton, X Liu, X Ye, AE Muruato, DC Ng, S Biswas, J Zou, ... Nature 595 (7869), 718-723, 2021 | 147 | 2021 |
| A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses Y Cai, Z Ku, Q Liu, Q Leng, Z Huang Vaccine 32 (21), 2406-2412, 2014 | 104 | 2014 |
| A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge Q Liu, K Yan, Y Feng, X Huang, Z Ku, Y Cai, F Liu, J Shi, Z Huang Vaccine 30 (47), 6642-6648, 2012 | 96 | 2012 |
| A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice Z Ku, Q Liu, X Ye, Y Cai, X Wang, J Shi, D Li, X Jin, W An, Z Huang Vaccine 32 (34), 4296-4303, 2014 | 87 | 2014 |
| Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection Y Cai, Q Liu, X Huang, D Li, Z Ku, Y Zhang, Z Huang Vaccine 31 (18), 2215-2221, 2013 | 87 | 2013 |
| Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre-and post-attachment steps Z Ku, X Ye, X Huang, Y Cai, Q Liu, Y Li, Z Su, Z Huang PLoS One 8 (2), e57601, 2013 | 80 | 2013 |
| Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms X Ye, Z Ku, Q Liu, X Wang, J Shi, Y Zhang, L Kong, Y Cong, Z Huang Journal of virology 88 (1), 72-81, 2014 | 76 | 2014 |
| High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice C Zhang, Z Ku, Q Liu, X Wang, T Chen, X Ye, D Li, X Jin, Z Huang Vaccine 33 (20), 2335-2341, 2015 | 74 | 2015 |
| Detection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins Q Liu, Z Ku, Y Cai, B Sun, Q Leng, Z Huang Journal of virological methods 173 (1), 115-120, 2011 | 58 | 2011 |
| Single neutralizing monoclonal antibodies targeting the VP1 GH loop of enterovirus 71 inhibit both virus attachment and internalization during viral entry Z Ku, X Ye, J Shi, X Wang, Q Liu, Z Huang Journal of Virology 89 (23), 12084-12095, 2015 | 54 | 2015 |
| Transcutaneous immunization via rapidly dissolvable microneedles protects against hand-foot-and-mouth disease caused by enterovirus 71 Z Zhu, X Ye, Z Ku, Q Liu, C Shen, H Luo, H Luan, C Zhang, S Tian, ... Journal of Controlled Release 243, 291-302, 2016 | 53 | 2016 |
| Structural basis for recognition of human enterovirus 71 by a bivalent broadly neutralizing monoclonal antibody X Ye, C Fan, Z Ku, T Zuo, L Kong, C Zhang, J Shi, Q Liu, T Chen, Y Zhang, ... PLoS pathogens 12 (3), e1005454, 2016 | 51 | 2016 |
| Oncostatin M receptor–targeted antibodies suppress STAT3 signaling and inhibit ovarian cancer growth A Geethadevi, A Nair, D Parashar, Z Ku, W Xiong, H Deng, Y Li, J George, ... Cancer research 81 (20), 5336-5352, 2021 | 45 | 2021 |
| Development of murine monoclonal antibodies with potent neutralization effects on enterovirus 71 Z Ku, J Shi, Q Liu, Z Huang Journal of virological methods 186 (1-2), 193-197, 2012 | 44 | 2012 |
| Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants WR Strohl, Z Ku, Z An, SF Carroll, BA Keyt, LM Strohl BioDrugs 36 (3), 231-323, 2022 | 39 | 2022 |
Zhiqiang AnProfessor of Molecular Medicine, University of Texas Health Science Center at HoustonVerified email at uth.tmc.edu